Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Healthcare Biotechnology

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

Bullboard Posts

Comment by Riverfolkon Mar 31, 2020 5:05pm

98 Views

Post# 30865948

RE:RE:RE:Arch Biopartners Releases New Video Showing Metablok Reducin

The past 6 months has been low volume, while long term shareholders wait patiently. The stock was dripping on small trades until mid March. This play went from .70 to 1.80 in a month because of a drug development.

Now, Arch has a safe drug for humans, a patented drug library and potentially a treatment for a world wide pandemic. I think this thing is going to blow past the old high.

Management committed in this news release to helping with treatment, if anyone wants a large position, better get in now. This is a billion dollar revenue annually type drug, we are trading at 50mil market cap.

Bullboard Posts

Full Circle Lithium goes global with its battery fire-fighter